by | May 18, 2024 | Publications
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241252605. doi: 10.1177/15330338241252605. ABSTRACT OBJECTIVE: 1q21 gain/Amp is one of the most common cytogenetic abnormalities. There are controversies about its effects on prognosis and may be associated with...
by | May 17, 2024 | Publications
Expert Opin Biol Ther. 2024 May 17. doi: 10.1080/14712598.2024.2357382. Online ahead of print. ABSTRACT INTRODUCTION: Gain/amplification of 1q (+1q) represents one of the most prevalent cytogenetic abnormalities (CAs) observed in multiple myeloma (MM). Historical...
by | May 17, 2024 | Publications
Cancer Immunol Immunother. 2024 May 17;73(7):135. doi: 10.1007/s00262-024-03711-8. ABSTRACT BACKGROUND: Isatuximab, an anti-CD38 antibody, has been widely used in treatments for patients with relapsed/refractory multiple myeloma (MM). Despite its high efficacy, not...
by | May 17, 2024 | Publications
Exp Ther Med. 2024 Apr 29;27(6):269. doi: 10.3892/etm.2024.12557. eCollection 2024 Jun. ABSTRACT Multiple myeloma (MM) is a plasma cell clonal disease and these plasma cells can survive in the gut. The intestinal microbiota is a complex ecosystem and its dysfunction...
by | May 17, 2024 | Publications
Cancer Sci. 2024 May 16. doi: 10.1111/cas.16198. Online ahead of print. ABSTRACT The anti-CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT)...
by | May 17, 2024 | Publications
Nat Commun. 2024 May 16;15(1):4139. doi: 10.1038/s41467-024-47793-5. ABSTRACT The natural history of multiple myeloma is characterized by its localization to the bone marrow and its interaction with bone marrow stromal cells. The bone marrow stromal cells provide...
